Reaction profile
The FDA adverse-event record for injection site serosanguinous discharge
283 FDA adverse-event reports reference injection site serosanguinous discharge (VeDDRA 104). Plate codes and volume neighbourhood below; species, breeds, and drugs follow.
- #895 of 2,481
- by report volume (all reactions)
- 283
- reports citing this reaction
- 7.8%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Injection site serosanguinous discharge has 283 reports now versus 278 in that prior snapshot: 5 more (1.8%).
- Report change
- +5
- Death-coded reports
- +0
- Death-coded share
- −0.1 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Injection site serosanguinous discharge changesFDA AER · VeDDRA plate
Code 104 VOL-LOW
VOL-LOW · DEATH-PAR · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-LOW 283 reports
- DEATH-PAR 7.8%
- MID-PACK #895/2481
- PHOTO-FINISH Cardiomyopathy
- SPECIES-DOG Dog · 270
- DRUG-LEAD Tigilanol Tiglate · 146
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Cardiomyopathy (±0 reports)
Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.
Report-volume neighbourhood around Injection site serosanguinous discharge
Highest and lowest poles plus nearest volume peers, not a full 2,500-reaction corpus board reprint.
Injection site serosanguinous discharge: low death-coded share in the FDA AER plate
Signature read: Injection site serosanguinous discharge's 7.8% death-coded share is among the lowest in the openFDA reaction corpus. Report volume sits in the middle third of the reaction corpus. Death-coded share is lower-third: 22 of 283 reports (7.8% of named reports). Nearest volume peer: Cardiomyopathy (±0 reports). Lead species Dog (270). Lead co-reported drug Tigilanol Tiglate (146).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Tigilanol Tiglate appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Injection site serosanguinous discharge, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (283 here).
Similar death-coded share
Nearest other reactions by death-coded share (7.8% here), distinct from the volume row.
What to do with this reaction
- Compare Injection site serosanguinous discharge's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →